Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score
- PMID: 33632764
- PMCID: PMC7908055
- DOI: 10.1136/thoraxjnl-2020-216001
Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score
Abstract
Objective: To develop and validate a prediction model of mortality in patients with COVID-19 attending hospital emergency rooms.
Design: Multivariable prognostic prediction model.
Setting: 127 Spanish hospitals.
Participants: Derivation (DC) and external validation (VC) cohorts were obtained from multicentre and single-centre databases, including 4035 and 2126 patients with confirmed COVID-19, respectively.
Interventions: Prognostic variables were identified using multivariable logistic regression.
Main outcome measures: 30-day mortality.
Results: Patients' characteristics in the DC and VC were median age 70 and 61 years, male sex 61.0% and 47.9%, median time from onset of symptoms to admission 5 and 8 days, and 30-day mortality 26.6% and 15.5%, respectively. Age, low age-adjusted saturation of oxygen, neutrophil-to-lymphocyte ratio, estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, dyspnoea and sex were the strongest predictors of mortality. Calibration and discrimination were satisfactory with an area under the receiver operating characteristic curve with a 95% CI for prediction of 30-day mortality of 0.822 (0.806-0.837) in the DC and 0.845 (0.819-0.870) in the VC. A simplified score system ranging from 0 to 30 to predict 30-day mortality was also developed. The risk was considered to be low with 0-2 points (0%-2.1%), moderate with 3-5 (4.7%-6.3%), high with 6-8 (10.6%-19.5%) and very high with 9-30 (27.7%-100%).
Conclusions: A simple prediction score, based on readily available clinical and laboratory data, provides a useful tool to predict 30-day mortality probability with a high degree of accuracy among hospitalised patients with COVID-19.
Keywords: clinical epidemiology; critical care; emergency medicine; pneumonia; respiratory infection; viral infection.
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: JB reports grants and personal fees from GILEAD, MSD and ViiV Healthcare; and personal fees from JANSSEN, outside the submitted work. PR reports grants and personal fees from GILEAD and MSD; and personal fees from AbbVie and ViiV Healthcare, outside the submitted work. IJ reports personal fees from GILEAD and ViiV Healthcare, outside the submitted work. JRA reports grants and personal fees from GILEAD and ViiV Healthcare; and personal fees from ALEXA, MSD, JANSSEN, SERONO and TEVA, outside the submitted work. The remaining authors have nothing to disclose.
Figures


Similar articles
-
Development and external validation of a prediction risk model for short-term mortality among hospitalized U.S. COVID-19 patients: A proposal for the COVID-AID risk tool.PLoS One. 2020 Sep 30;15(9):e0239536. doi: 10.1371/journal.pone.0239536. eCollection 2020. PLoS One. 2020. PMID: 32997700 Free PMC article.
-
A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study.J Immunother Cancer. 2020 Sep;8(2):e001314. doi: 10.1136/jitc-2020-001314. J Immunother Cancer. 2020. PMID: 32895296 Free PMC article.
-
Development and external validation of a COVID-19 mortality risk prediction algorithm: a multicentre retrospective cohort study.BMJ Open. 2020 Dec 24;10(12):e044028. doi: 10.1136/bmjopen-2020-044028. BMJ Open. 2020. PMID: 33361083 Free PMC article.
-
IL-6-based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts.J Allergy Clin Immunol. 2021 May;147(5):1652-1661.e1. doi: 10.1016/j.jaci.2021.02.021. Epub 2021 Mar 1. J Allergy Clin Immunol. 2021. PMID: 33662370 Free PMC article. Clinical Trial.
-
Primary Care Relevant Risk Factors for Adverse Outcomes in Patients With COVID-19 Infection: A Systematic Review.J Am Board Fam Med. 2021 Feb;34(Suppl):S113-S126. doi: 10.3122/jabfm.2021.S1.200429. J Am Board Fam Med. 2021. PMID: 33622826
Cited by
-
External validation of the 4C Mortality Score for hospitalised patients with COVID-19 in the RECOVER network.BMJ Open. 2022 Apr 21;12(4):e054700. doi: 10.1136/bmjopen-2021-054700. BMJ Open. 2022. PMID: 35450898 Free PMC article.
-
Development and Validation of an Acute Respiratory Distress Syndrome Prediction Model in Coronavirus Disease 2019: Updated Lung Injury Prediction Score.Mayo Clin Proc. 2023 May;98(5):736-747. doi: 10.1016/j.mayocp.2022.11.021. Epub 2022 Dec 30. Mayo Clin Proc. 2023. PMID: 37028977 Free PMC article.
-
[Predicting COVID-19 progress with clinical scales].Rev Clin Esp. 2022 Jan;222(1):42-43. doi: 10.1016/j.rce.2021.08.001. Epub 2021 Sep 1. Rev Clin Esp. 2022. PMID: 34483348 Free PMC article. Spanish. No abstract available.
-
Modeling for Prediction of Mortality Based on past Medical History in Hospitalized COVID-19 Patients: A Secondary Analysis.Can J Infect Dis Med Microbiol. 2024 Jul 2;2024:3256108. doi: 10.1155/2024/3256108. eCollection 2024. Can J Infect Dis Med Microbiol. 2024. PMID: 38984269 Free PMC article.
-
Outcome prediction in hospitalized COVID-19 patients: Comparison of the performance of five severity scores.Front Med (Lausanne). 2023 Feb 8;10:1121465. doi: 10.3389/fmed.2023.1121465. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36844229 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical